Manuscripts
Showing 1596 manuscripts.
Molecular detection of Mycobacterium tuberculosis from stool in young children using a novel centrifugation-free processing method
Citation
E Walters, L Scott, P Nabeta, AM Demers, G Reubenson, C Bosch, A David, M van der Zalm, J Havumaki, M Palmer, AC Hesseling, J Ncayiyana, W Stevens, D Alland, C Denkinger, P Banada. Molecular detection of Mycobacterium tuberculosis from stool in young children using a novel centrifugation-free processing method. Journal of Clinical Microbiology. 2018 Aug 27; 56(9):e00781-18. PMID: 29997199; PMCID: PMC6113478.Year
2018
Journal
Journal of Clinical Microbiology
Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV
Citation
Jeremiah D Momper, Brookie M Best, Jiajia Wang, Edmund V Capparelli, Alice Stek, Emily Barr, Martina L Badell, Edward P Acosta, Murli Purswani, Elizabeth Smith, Nahida Chakhtoura, Kyunghun Park, Sandra Burchett, David E Shapiro, Mark Mirochnick, IMPAACT P1026s Protocol Team. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018 Nov 13; 32(17):2507-2516. PMID: 30134297; PMCID: PMC6209536.Year
2018
Journal
AIDS
Study
P1026S
Development and application of a multiplex assay for the simultaneous measurement of antibodyresponses elicited by common childhood vaccines.
Citation
HL Itell, EP McGuire, CK Cunningham, EJ McFarland, W Borkowsky, SR Permar, GG Fouda. Development and application of a multiplex assay for the simultaneous measurement of antibodyresponses elicited by common childhood vaccines. Vaccine. 2018 Sep 05; 36(37):5600-5608. PMID: 30087048; PMCID: PMC6130906.Year
2018
Journal
Vaccine
Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children.
Citation
K Patel, J Lindsey, K Angelidou, G Aldrovandi, P Palumbo, IMPAACT P1060 Study team. Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children. AIDS. 2018 Oct 23; 32(16):2327-2336. PMID: 30102656; PMCID: PMC6170714.Year
2018
Journal
AIDS
Study
P1060
Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood
Citation
Jincheng Yang, Mina Nikanjam, Brookie M Best, Jorge Pinto, Ellen G Chadwick, Eric S Daar, Peter L Havens, Natella Rakhmanina, Edmund V Capparelli. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. Journal of Clinical Pharmacology. 2018 Dec 01; 58(12):1604-1617. PMID: 30252146; PMCID: PMC6604805.Year
2018
Journal
Journal of Clinical Pharmacology
Study
P1030, P1038, P1083
Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.
Citation
Weinberg A, Huang S, Moscicki AB, Saah A, Levin MJ, IMPAACT P1085 Protocol Team. Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. AIDS. 2018 Apr 24; 32(7):851-860. PMID: 29424778; PMCID: PMC5869173.Year
2018
Journal
AIDS
Study
P1085
Quantification of variation and the impact of biomass in targeted 16S rRNA gene sequencing studies.
Citation
JM Bender, F Li, H Adisetivo, D Lee, S Zabih, L Hung, TA Wiklinson, PS Pannaraj, RC She, JD Bard, NH Tobin, GM Aldrovandi. Quantification of variation and the impact of biomass in targeted 16S rRNA gene sequencing studies. Microbiome. 2018 Sep 10; 6(1):155. PMID: 30201048; PMCID: PMC6131952.Year
2018
Journal
Microbiome
Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations.
Citation
NT Ho, F Li, KA Lee-Sarwar, HM Tun, BP Brown, PS Pannaraj, JM Bender, MB Azad, AL Thompson, ST Weiss, MA Azcarate-Peril, AA Litonjua, AL Kozyrskyi, HB Jaspan, GM Aldrovandi, L Kuhn. Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations. Nature Communications. 2018 Oct 09; 9(1):4169. PMID: 30301893; PMCID: PMC6177445.Year
2018
Journal
Nature Communications
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Citation
S Nachman, C Alvero, H Teppler, B Homony, AJ Rodgers, BL Graham, T Fenton, LM Frenkel, RS Browning, R Hazra, AA Wiznia, IMPAACT 1066 Study Team. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial. Lancet HIV. 2018 Dec 04; 5(12):e715-e722. PMID: 30527329; PMCID: PMC6537590.Year
2018
Journal
Lancet HIV
Study
P1066